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Methods: Micelles of amphiphilic block copolymer poly (D, L-
lactide)-b-poly (N-vinylpyrrolidone-co-N-acryloxysuccinimide)
(PLA-b-P (NVP-co-NAS), 19000–22000 g.mol - 1, PDI= 1.5) were
prepared by nanoprecipitation and characterized in terms of size
(DLS) and critical micellar concentration (cmc). Imiquimod was
incubated with the aqueous micellar solution for 1 hour and
imiquimod loading in the micelles was quantiﬁed by ﬂuorimetry.
The micelles were further surface functionalized p24 antigen,
through amine reaction with the N-succinimidyl esters of the
NAS units at micelle surface in PBS pH 7.4 for 20 hours. Protein
coupling on the micelles were investigated by SDS-PAGE. The
expression of DC maturation/activation markers CD80, CD83,
CD86 induced by the micelles was assessed in vitro by ﬂow
cytometry.
Results: The micelles initially prepared from the PLA-b-P(NVP-
co-NAS) copolymer exhibited a mean diameter of 58 nm and a
CMC of 20mg.mL - 1 . Hydrophobic imiquimod was encapsu-
lated at a loading of 1.5% (w/w). The imiquimod-loaded micelles
were further highly surface-functionalized with p24 antigen, at a
level of 0.12mg p24 per mg of micelle, with a ﬁnal size of 110 nm.
Imiquimod encapsulated in the micelles was shown to induce
up-regulation of the DC maturation markers.
Conclusion: Such novel micelle-based systems could thus be
promising for vaccine delivery, particularly considering their
ability to potentially reach DCs in the lymph nodes, due to their
small size ( < 120 nm).
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Background: The RV144 trial is the only HIV vaccine clinical trial
to show evidence that a vaccine can prevent HIV infection. We
aligned the V2 reagents with odds ratios (OR) lower than 0.5
reported in the RV144 immune correlates study, and we deter-
mined that at least some protective antibodies (Abs) from the
RV144 trial target the peptide segment from positions 165–181 of
the V2 loop (V2 165–181), which is centered on the V1V2 do-
main’s C ß–strand. Thus, vaccine immunogens that exclusively
present V2 165–181 may preferentially elicit Abs that protect
against HIV infection.
Methods:We fused aV2 165–181 peptide to a non-HIV scaffold in
a manner that recapitulates the conformation of this segment in
the native folded V1V2 domain. We tested this designed immu-
nogen by immunization in rabbits using a DNA prime-protein
boost approach.
Results: We found that IgG from the immunized rabbits’ sera
bound a cyclic V2 peptide with high endpoint titers and neu-
tralized Tier 1 HIV viruses from subtypes B, C and AG.
Conclusion: Our data demonstrate that Abs elicited from a
synthetic peptide consisting of only the key C ß-strand-
centered segment of the V1V2 domain can bind to V2 165–181
in its native context within the HIV virus, and in some cases
can neutralize the virus. Our results provide proof of concept
that a V2 165–181 immunofocused immunogen, which can be
further designed to preferentially present the epitopes associ-
ated with protection in the RV144 trial, can elicit neutralizing
antibodies.
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Background: The membrane-proximal external region (MPER) is
an important vaccine target because it is a well-conserved ele-
ment of Env that is recognized by several broadly neutralizing
monoclonal antibodies. Moreover, MPER-speciﬁc neutralizing
antibodies are generated in some HIV-infected patients empha-
sizing that the human immune system does recognize MPER
structures presented on HIV particles and infected cells. Because
the native MPER structure is dependent on its association with
the lipid bilayer, we have developed plasmid DNA and live
VSV vectors that express the MPER as a membrane-anchored
immunogen.
Methods: The transmembrane domain and cytoplasmic tail of
VSV G were used as a platform (G-stem) for surface expression
of an ectodomain composed primarily of MPER sequence. Live
VSV and plasmid DNA vectors were constructed encoding
G-stemMPER immunogens.
Results: Plasmid DNA and VSV vectors were designed to
express G-StemMPER immunogens as integral membrane
proteins. The VSV vectors coexpress G-stemMPER and native
G, thus they are replication-competent. Western blot analysis
conducted with transfected or infected cells conﬁrmed ex-
pression of G-stemMPER proteins by both vectors, and ﬂow
cytometry showed that the MPER epitopes also were present
on the cell surface and bound to neutralizing monoclonal an-
tibodies. Consistent with G-stemMPER incorporation into the
cell plasma membrane, analysis of puriﬁed VSV vectors re-
vealed that the immunogen also was present in virus particles
along with native VSV G. A murine study is underway to
evaluate the immunogenicity of electroporated DNA prime
followed by an intranasal boost with replicating VSV-G-
StemMPER vectors and we are currently analyzing immune
responses.
Conclusion: Plasmid DNA and replicating VSV vectors ex-
pressed membrane-anchored G-stem-MPER which were anti-
genic and have been used to safely vaccinate mice. Data from the
ongoing murine immunogenicity study will determine if the G-
stemMPER immunogen strategy is an effective approach for in-
ducing antibodies with MPER speciﬁcity.
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Background: Despite decades of effort, no current vaccine elicits
neutralizing antibodies at concentrations blocking HIV infection.
In addition to structural features of HIV’s envelope spike that
facilitate antibody evasion, a hypothesis for the ineffective im-
mune response lies in the low density and limitedmobility of HIV
envelope spikes, which impedes bivalent binding by antibodies,
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reducing avidity, minimizing the potential for high afﬁnity
binding and virus neutralization.
Methods: We intend to engineer anti-HIV reagents that bind
with high avidity to single spikes, overcoming potential
problems with the low density of HIV spikes. Here, we dem-
onstrate a strategy to use dsDNA as a rigid molecular ruler to
map epitopes on the HIV envelope protein to gain insight into
the relatively unknown spatial environment of the spike tri-
mer. Upon determining the optimal separation distance be-
tween epitopes, the dsDNA linker will be replaced with a
structured protein linker. This technique should allow for the
development of a novel multivalent antibody reagent im-
proving binding and increasing avidity.
Results: Optimal HIV binding proteins will be trimerized by at-
taching a trimerization motif, reducing the concentration re-
quired for sterilizing immunity. To date, we have several
bispeciﬁc DNA reagents that have the ability to neutralize various
strains of HIV with greater potency than its individual compo-
nents.
Conclusion: These results demonstrate the promise for discovery
of optimal anti-HIV reagents using this technology.
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Background: A few stable regions have been discovered on the
envelope glycoproteins of HIV-1 against which some patients
produce neutralizing antibodies. The most promising epitopes
are located in the membrane proximal external region and are
probably exposed transiently during the fusion of cellular and
viral membranes. Whereas the peptides isolated from this region
failed to induce neutralizing immunogenic response. Previous
studies suggest that the lipid membrane plays a role in antigens
structure and in the immunogenic response developed by these
patients.
Methods:We investigate these epitopes (one from gp120 and two
from gp41) and their insertion into liposomal carriers by struc-
tural approaches (Nuclear Magnetic Resonance, Circular Di-
chroism: CD). This requires the production of the polypeptides by
bacterial over-expression and their puriﬁcation by using bio-
chemical methods, and their reconstitution into liposomal carri-
ers. In addition, the immunogenicity of these epitopes will be
investigated by mice immunization and the immune response
will be quantiﬁed by ELISA.
Results: The conditions for expression and puriﬁcation of these
polypeptides are established. The puriﬁed polypeptides solubi-
lised in detergent are reconstituted overnight into liposomal
carriers by a dialysis approach. Their secondary structure is in-
vestigated byCD. gp120 and gp41a adoptmainly an alpha-helical
structure in the detergent. In contact with the lipids, gp41a
maintains this helical structure and it is reinforced in liposomes
having a similar composition of the viral membrane. In contrast
the gp120 construct adopts a predominantly beta-sheet structure.
Conclusion: The comparative analysis of the potential for im-
munogenicity and structural results obtained will be confronted
in order to better understand the fusion of the cellular and viral
membranes and thereafter to help in the design of vaccines di-
rected against HIV-1.
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Background: The HIV epidemic continues to spread globally, thus
highlighting the need for the development of an effective HIV
vaccine, most especially for developing countries. Mycobacterium
bovis bacilli-Calmette-Guerin (BCG) has been widely used as an
HIV vaccine vector due to its proven safety record. However, high
level expression of viral antigens can often increase the metabolic
burden resulting in genetic instability and hence poor immune
responses. This study aimed to compare recombinant myco-
bacteria expressing HIV-1 gag under the control of different pro-
moters and leader sequences. This was done to determine whether
the genetic stability of the recombinant mycobacteria could be
improved by modiﬁcation of these vector features.
Methods: The optimal vector backbone was selected by stability
assays. A series of shuttle vectors with different promoters
(hsp60, psmcyc or mtrA) and leader sequences (a-antigen or
19kDa signal peptide) were constructed and their stability was
determined by means of relative colony size scoring and growth
curves. Lastly the immunogenicity of recombinant BCG expres-
sing HIV-1 Gag alone or Gag fused to either of the leader se-
quences was evaluated in mice.
Results: It was shown that the addition of various vector features
such as 19kDa/-a leader sequences and codon optimisation of
HIV-1 gag did not have an effect on vector stability as indicated
by the similar colony size score. Furthermore, the use of leader
peptides resulted in differential expression levels of Gag as
shown by p24 assays cultures with pEMaGag2(V3SV5) seamed to
express more Gag as compared to pEM19Gag2(V3SV5) and
pEMGag2(V3SV5) recombinants (64pg/ml as compared to 39
and 17 respectively).
Conclusion: Despite the low immune responses elicited by the
rBCG vaccines, the panBCG[pEMaGag2V3SV5] maybe a prom-
ising vaccine as seen by increased immune responses to the V3
CTL epitope as well as Gag p24 levels from M. smegmatis with
the same vector.
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